Lojuxta (lomitapide) capsules is a prescription medicine used along with diet and other lipid-lowering treatments, including low-density lipoprotein (LDL) apheresis where available, in adults with homozygous familial hypercholesterolaemia (HoFH).
Amryt Pharma holds an exclusive licence to sell lomitapide for adults across the EEA, Middle East, North Africa, Turkey and Israel.
Unlike other therapies, lomitapide does not work by trying to clear the high levels of cholesterol. It works by reducing the production and release of cholesterol from the liver and by reducing the absorption of cholesterol from the intestines following a meal. Specifically, lomitapide is a first in class oral, selective inhibitor of microsomal triglyceride transfer protein (MTP) a protein necessary for the proper assembly and secretion of apolipoprotein B (apo B)-containing lipoproteins in the liver and the intestines. Inhibition of MTP reduces lipoprotein secretion and circulating concentrations of lipoprotein‑borne lipids including cholesterol, LDL-C and triglycerides.
The European Commission (EC) granted authorisation for lomitapide under the trade name ‘Lojuxta’ in July 2013. Lojuxta is indicated as:
An adjunct to a low-fat diet and other lipid-lowering medicinal products with or without low density lipoprotein (LDL) apheresis in adult patients with homozygous familial hypercholesterolaemia (HoFH). Genetic confirmation of HoFH should be obtained whenever possible. Other forms of primary hyperlipoproteinemia and secondary causes of hypercholesterolaemia (e.g., nephrotic syndrome, hypothyroidism) must be excluded.
See the Summary of Product Characteristics for further information.